Latest News and Press Releases

Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital...

In the first half of 2024, Novonesis delivered 7% organic sales growth with an adjusted EBITDA margin at 35.3%. Following strong first half-year performance, Novonesis increases its full-year organic...

H1 organic pro forma sales growth at 7%, with pro forma adjusted EBITDA margin at 35.3%. Full-year outlook increased.   H1 organic pro forma sales growth of 7% and 8% on IFRS reported basis. Q2...

Novonesis increases its full-year sales and profitability outlook based on the first half year performance coupled with strong momentum going into the first months of the second half.The 2024 outlook...

Please see the full announcement in PDF  Attachments 2024_25_Major_Shareholders_Announcement Novozymes B 13 Aug 2024 Final ...

Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis, that as of June 21, BlackRock, Inc. crossed the 5% threshold...

In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016,...

June 21, 2024 Company announcement No. 22 Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that Novo Nordisk Fonden has on its own behalf and on behalf of its...

Novonesis is performing very well and the 2024 outlook for pro forma organic sales growth is now expected at the upper end of the 5-7% range while the pro forma adjusted EBITDA margin is increased to...

   June 6, 2024Company announcement No. 20  Incentive program for the Executive Leadership Team 2024-2026 In line with previous year, a new long-term incentive program (LTI) for the...